Market activity surges across the globe with several blockbuster listings on the horizon. In a major win for the London Stock Exchange, Norwegian software giant Visma is ditching Amsterdam to line up a €19 billion IPO in London. Meanwhile, the Asian markets are buzzing as fashion behemoth Shein prepares a landmark confidential filing in Hong Kong, a move expected to revitalize the city's capital markets. The U.S. also saw significant momentum, with travel tech firm Navan, previously valued at $9.2 billion, confidentially filing for its public debut.

In a Reuters article covering the strong market debut of Jefferson Capital, IPOX® Research Associate Lukas Muehlbauer provided commentary on the recovering U.S. IPO market. He noted the rebound is likely to be selective, "led by high-quality and long-anticipated issuers." Muehlbauer explained that an initial trading "pop" is part of the market's "healthy process of price discovery" to establish a sustainable price. Read more in the full article on the IPOX website.

In a recent Bloomberg article, IPOX® Research Associate Lukas Muehlbauer commented on the challenging European IPO market. Highlighting the recent withdrawal of several listings, Muehlbauer noted that investor appetite is particularly low for private equity exits where proceeds do not benefit the company. He stated, “Deals that are essentially existing owners cashing out are proving to be a tough sell.” Read more about his analysis of the current market sentiment on our blog.

The IPOX® 100 U.S. Index (ETF: FPX) is opening at a new all-time high, extending its year-to-date gain to +21%. This surge is driven by positive market sentiment, end-of-quarter positioning, and reassuring inflation comments from the FED. Other key indexes, including the IPOX® International (FPXI) and IPOX® 100 Europe (FPXE), also closed at multi-year highs, reflecting broad strength across the IPOX® portfolio and its position as the gold standard for IPOs.

IPOX® Research Associate Lukas Muehlbauer commented on the news of Wealthfront Corporation's confidential U.S. IPO filing in a Reuters article on June 23, 2025. He noted that the move is consistent with a recent positive trend in the market, stating, "Wealthfront's IPO plans fit in with the recent uptick of successful U.S. IPOs, particularly from sectors insulated from trade and supply chain volatility."

High-value listings are planned in Europe, including BioMar's potential $2B IPO. Hong Kong remains a key venue for Asian firms like FWD Group and MiniMax. While the U.S. market sees lower volumes and volatility, the MENA region experienced a shaky debut for Flynas. Highlighting future activity, mining giant Vale's metals unit is preparing for a potential landmark $25B IPO, signaling significant deals ahead.

In a Reuters article on Slide Insurance's $2.6 billion IPO, IPOX® Vice President Kat Liu provided expert insights. Liu commented on the firm's niche strategy in high-risk coastal markets and the appeal of insurer IPOs due to predictable cash flows. She also offered perspective on potential governance concerns at the newly public company, highlighting IPOX's expertise in analyzing new listings and market trends in the global financial sector.

In a recent Bloomberg feature, IPOX® Founder and CEO Josef Schuster analyzed the potential IPO of Vale SA’s base metals unit. He noted a listing based on its $25 billion valuation could be the most valuable mining stock debut since Glencore Plc in 2011, stating it “would definitely rank amongst the top 10 mining IPOs.” This commentary underscores the historic scale of the potential offering in the global materials sector. Read more here.

IPOX® Research Associate Dr. Lukas Muehlbauer provided commentary for Bloomberg News on the volatile debut of Saudi Arabian low-cost carrier Flynas and the company's resilience in the face of increased regional instability.

IPOX® Research Associate Dr. Lukas Muehlbauer commented on the U.S. IPO filing of Australian meat producer Kilcoy Global Foods. The article discusses the recent resurgence in the U.S. IPO market and notes that Kilcoy's listing will be a significant indicator of investor appetite for companies with intricate global supply chains.

The IPO market is showing strong signs of a rebound in mid-2025, fueled by improving economic stability and renewed investor confidence. After a period of caution, a solid pipeline of companies, particularly in the technology and life sciences sectors, is now emerging. High-profile debuts have performed well, encouraging other unicorns to accelerate their listing plans. While market volatility remains a consideration, the overall sentiment is optimistic for a more active and receptive second half.

In a Reuters article covering Chime’s IPO, IPOX® VP Kat Liu, provided expert commentary on the implications of the company’s strong market reception. Ms. Liu noted that the performance of a high-profile "unicorn" like Chime is being closely watched and could encourage other private fintech companies to move forward with their own public offerings.

In a Reuters article covering the successful market debut of Voyager Technologies, IPOX® Associate Lukas Muehlbauer was quoted in the piece, stating, "Strategic government backing amid increased defense spending somewhat shields these [defense] firms from tariff-induced supply chain risks." His analysis underscores the unique factors contributing to the resilience and attractiveness of companies within the sector.

In a recent Bloomberg article, IPOX® Founder Josef Schuster provided his expert commentary on the U.S. IPO market's recent surge in performance. He described a "positive feedback loop" where unsatisfied demand for one hot listing is driving investor orders for the next, contributing to the market's momentum. Schuster noted that while this enthusiasm is promising, the true test for the recovery will be the fundamental strength shown in the first quarterly earnings from these newly public companies, stating, "When you see the first set of earnings from some of these companies, you will really see how substantial this recovery of the IPO market is going to be."

In a recent Reuters article, IPOX® VP Kat Liu, provided commentary on the upcoming IPO of property insurance technology company Slide. The company is reportedly targeting a valuation of up to $2.12 billion and aims to raise as much as $340 million.

In a recent report by Reuters, IPOX® Research Associate Dr. Lukas Muehlbauer provided commentary on the upcoming U.S. initial public offering of cancer diagnostic firm Caris Life Sciences. The company is aiming for a valuation of up to $5.3 billion, seeking to raise as much as $423.5 million.